146 related articles for article (PubMed ID: 34511623)
1. Tumor Lysis Syndrome due to Eribulin Administration for Metastatic Undifferentiated Pleomorphic Sarcoma of the Buttock.
Tsuchie H; Miyakoshi N; Nagasawa H; Shimada Y
Acta Med Okayama; 2021 Aug; 75(4):533-538. PubMed ID: 34511623
[TBL] [Abstract][Full Text] [Related]
2. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.
Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P;
Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277
[TBL] [Abstract][Full Text] [Related]
3. Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma.
Kobayashi H; Okuma T; Oka H; Okajima K; Ishibashi Y; Zhang L; Hirai T; Ohki T; Tsuda Y; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Kawano H; Goto T; Tanaka S
Int J Clin Oncol; 2019 Apr; 24(4):437-444. PubMed ID: 30465138
[TBL] [Abstract][Full Text] [Related]
4. Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma.
Pabon C; Esnakula AK; Daily K
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30573532
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
6. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
[TBL] [Abstract][Full Text] [Related]
7. Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.
De Vita A; Recine F; Mercatali L; Miserocchi G; Spadazzi C; Liverani C; Bongiovanni A; Pieri F; Casadei R; Riva N; Fausti V; Amadori D; Ibrahim T
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29292724
[TBL] [Abstract][Full Text] [Related]
8. Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
Tsuchihashi K; Kusaba H; Yoshihiro T; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Imajima T; Shinohara Y; Ito M; Yamaga S; Tanoue K; Arimizu K; Ohmura H; Hanamura F; Yamaguchi K; Isobe T; Ariyama H; Nakashima Y; Akashi K; Baba E
Sci Rep; 2020 Dec; 10(1):20896. PubMed ID: 33262403
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
Emambux S; Italiano A
Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ratan R; Patel SR
Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249
[TBL] [Abstract][Full Text] [Related]
11. Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment.
Takada K; Murase K; Nakamura H; Hayasaka N; Arihara Y; Iyama S; Ikeda H; Emori M; Sugita S; Nakamura K; Miyanishi K; Kobune M; Kato J
Intern Med; 2019 Oct; 58(20):3009-3012. PubMed ID: 31243217
[TBL] [Abstract][Full Text] [Related]
12. Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case report.
Caputo R; Cianniello D; De Laurentiis M
Future Oncol; 2017 Apr; 13(11s):45-50. PubMed ID: 28481184
[TBL] [Abstract][Full Text] [Related]
13. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
[TBL] [Abstract][Full Text] [Related]
14. Eribulin-based treatment in patients affected by sarcomas: a case series.
Grignani G; D'Ambrosio L
Future Oncol; 2020 Jan; 16(1s):1-3. PubMed ID: 31840540
[No Abstract] [Full Text] [Related]
15. Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Barni S; Livraghi L; Gravina A; Martella F; D'Onofrio L; Morritti M; Michelotti A; Vici P; Mentuccia L; Porcu L; Orditura M; Puglisi F;
J Geriatr Oncol; 2019 Nov; 10(6):990-993. PubMed ID: 31097340
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
de Nonneville A; Sabatier R; Gonçalves A; Extra JM; Tarpin C; Launay S; Tassy L; Viens P; Rousseau F
J Geriatr Oncol; 2018 May; 9(3):281-283. PubMed ID: 29174186
[No Abstract] [Full Text] [Related]
17. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study.
Kawai A; Narahara H; Takahashi S; Nakamura T; Kobayashi H; Megumi Y; Matsuoka T; Kobayashi E
BMC Cancer; 2022 May; 22(1):528. PubMed ID: 35546669
[TBL] [Abstract][Full Text] [Related]
20. The safety of eribulin for the treatment of metastatic breast cancer.
Perez-Garcia JM; Cortes J
Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
[No Abstract] [Full Text] [Related]
[Next] [New Search]